Search clinical trials for: Apatinib

Total 540 results

Shandong Cancer Hospital and Institute
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Elevar Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Adenoid Cystic Carcinoma

United States, Korea, Republic of
Beijing Sanbo Brain Hospital

Completed

Glioblastoma Response Prediction to Apatinib

Glioblastoma

China
Tianjin Medical University Cancer Institute and...

Active, not recruiting

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Gastric Cancer Stage IV

China
Shenzhen People's Hospital

Suspended

Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C) (BABST-C)

Colorectal Neoplasms

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Breast Cancer | Triple Negative Breast Cancer

China
Sun Yat-sen University

Active, not recruiting

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Nasopharyngeal Carcinoma | Chemotherapy Effect | Immunotherapy | Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma | Molecular Targeted Therapy

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Hepatocellular Carcinoma (HCC)

China
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Completed

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Active, not recruiting

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

Breast Cancer

China
Peking Union Medical College Hospital

Active, not recruiting

Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer

Differentiated Thyroid Cancer

China
Sun Yat-sen University

Completed

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

Recurrent Cervical Carcinoma | Metastatic Cervical Cancer

China
Elevar Therapeutics

Completed

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)

Hepatocellular Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.
Eighty-One Hospital of People's Liberation Army

Completed

A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

China
Yuhong Li

Completed

Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment (Poetry-1)

Esophageal Squamous Cell Carcinoma

China
Huashan Hospital

Completed

mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

Apatinib

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Advanced Biliary Tract Carcinoma | Advanced Primary Liver Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy (PASSION)

Small-cell Lung Cancer

China
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial...

Active, not recruiting

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

Colorectal Cancer | Microsatellite Instability High

China
Tianjin Medical University Cancer Institute and...

Completed

Chemotherapy Combined With Apatinib and PD-1 Antibody

Gastric Cancer

China
Wei Jiang
Wuzhou Red Cross Hospital; Laibin People's Hospital; Guangxi Naxishan Hospital; People's Hospital of Lingshan

Completed

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Johns Hopkins University
Medical University of South Carolina; Children's Hospital of Philadelphia; Washington... and other collaborators

Completed

Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease (HUPrevent)

Stroke | Sickle Cell Disease

United States
Hunan Cancer Hospital
Suzhou Sheng Diya Biomedical Co., Ltd.

Active, not recruiting

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Adenocarcinoma of the Lung

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors

Neoplasm Malignant | Tumor, Solid | Cancer, Metastatic

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma (HCC)

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Triple Negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.

Solid Tumor, Adult

China
Bukwang Pharmaceutical

Completed

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

Gastric Cancer

Korea, Republic of
Fan Yun, MD

Completed

Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.

Small Cell Lung Cancer

China
Elevar Therapeutics

Completed

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer (ANGEL)

Gastric Cancer | Gastric Adenocarcinoma

United States, United Kingdom, Korea, Republic of, France, Taiwan, Japan, Russian Federation, Germany, Italy, Poland, Romania, Ukraine
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

China
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Completed

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Ovarian Cancer | Triple Negative Breast Cancer

China
Sun Yat-sen University

Active, not recruiting

Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Nasopharyngeal Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

China
Fudan University

Completed

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Advanced Triple-Negative Breast Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Withdrawn

A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib

Esophageal Neoplasms
Elevar Therapeutics

Completed

A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants

Healthy

United States
Elevar Therapeutics

Terminated

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer (APPROVE)

Platinum-resistant Recurrent Ovarian Cancer

China
Lei Li

Completed

First-line Chemotherapy for Recurrent Cervical Cancer

Chemotherapy | Recurrent Cervical Carcinoma | Apatinib | Targeted Therapy | Persistent Advanced Cervical Carcinoma | Vascular Endothelial Growth Factor 2 Inhibitor

China
Affiliated Hospital of Qinghai University

Completed

Apatinib for the Elderly Advanced Gastric Cancer

Gastric Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

Other Infectious Diseases

United States
Peking University People's Hospital
Peking University Shougang Hospital

Completed

Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma

Effect of Drug | Toxicity, Drug | Secondary Resistance

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer

Gastric Cancer

China
Hubei Cancer Hospital

Enrolling by invitation

Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

NSCLC

China
Guangdong Provincial People's Hospital

Completed

Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer (LANCET)

Triple-Negative Breast Cancer

China

Search clinical trials for: Apatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations